Year: 2025

PrivacyKey™ recognized for delivering fast, secure, privacy-first biometric authentication that enhances trust across digital payments DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced that its flagship product PrivacyKey™ has been named Best Digital Trust Solution – ID Verification & Authentication by Fintech Futures for the 2025 PayTech Awards, which celebrate excellence and innovation in the global payments and fintech industry. PrivacyKey delivers sub-second, deterministic biometric authentication with a privacy-first approach that ensures users are who they claim to be, while safeguarding sensitive data and meeting global compliance standards. By combining liveness detection, advanced biometric...

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY™ Sildenafil...

SALT LAKE CITY, Dec. 10, 2025 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming Water Tower Fireside Chat Series on Thursday, December 11, 2025. The webcast of the fireside chat will begin at approximately 2:00 p.m. Eastern Time on Thursday, December 11, 2025. The event is open access for all investors and interested parties can register directly here or through the Company’s Investor Relations website at https://investor.lifevantage.com/events-and-presentations. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is...

// Not for distribution to the United States newswire services or for dissemination in the United States // VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — Copper Quest Exploration Inc. (CSE: CQX; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that it has completed its positive due diligence of the arms-length Option to Purchase Agreement (the “Agreement“) dated November 7th, 2025 and previously announced November 14, 2025. The Agreement is with 0847114 B.C. Ltd. (“Privco“), a British Columbia Incorporated company that holds 100% ownership, title, and interest in the Alpine Gold Property (the “Property“), located in the West Kootenay region of British Columbia (the “Acquisition“). The Company plans to immediately begin the process to complete the...

MILWAUKEE, Dec. 10, 2025 (GLOBE NEWSWIRE) — Enerpac Tool Group Corp. (NYSE: EPAC) announced today that it will release its first quarter fiscal 2026 earnings after the market closes on Wednesday, December 17, 2025. Management will conduct a conference call to discuss the results on Thursday, December 18, 2025, beginning at 8:30 a.m. ET / 7:30 a.m. CT. A real-time webcast of the conference call can be accessed via the Investors section of the Company’s website. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call for 90 days. About Enerpac Tool Group Enerpac Tool Group Corp. is a premier industrial tools, services, technology, and solutions provider serving a broad and diverse set of customers and end markets for mission-critical applications in more than 100 countries....

STILLWATER, Okla., Dec. 10, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company) today announced a significant acceleration of the commercialization timeline for its Round Top heavy rare earth deposit in Texas. The Company now plans to begin commercial production in late 2028, two years earlier than previously anticipated. Round Top is the United States’ richest known deposit of heavy rare earth elements, gallium, and beryllium, and is a cornerstone of USAR’s integrated mine-to-magnet value chain. That value chain also includes a 310,000 sq ft. magnet manufacturing facility in Stillwater, Oklahoma, which is expected to be the largest metal-and-alloy-making and strip-casting capability outside of China, and a processing and separation laboratory in Wheat Ridge, Colorado. “We’re challenging ourselves...

TransUnion also projects delinquency expectations for other major credit products during the next year CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today released its 2026 Consumer Credit Forecast, projecting credit card balances to grow 2.3% year over year (YoY)—the smallest annual increase since 2013, excluding 2020 when pandemic relief programs caused a decline. This moderation reflects consumers navigating persistent economic uncertainty as lenders maintain disciplined underwriting standards. Credit card balances are expected to reach $1.18 trillion by the end of 2026, up from $1.16 trillion in 2025. This increase contrasts sharply with the double-digit growth of 2022 and 2023, but reflects the more modest pace of growth seen in more recent years. Lenders are cautiously expanding credit access for riskier...

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3 Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease1 ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment4-7 Data will be featured in an oral presentation at the 2025 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 10 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people...

Kraken Robotics Inc. announces the successful demonstration of its KATFISH Unmanned Surface Vessel Launch and Recovery System (USV-LARS) from TKMS ATLAS UK’s (ATLAS UK) 11-meter ARCIMS USV. The systems offer a comprehensive autonomous survey package for maritime security missions including mine countermeasure operations and critical underwater infrastructure inspection. Together, ARCIMS and KATFISH USV-LARS provide the industry’s first air-deployable, 300-meter depth rated autonomous towed SAS survey system.ST. JOHN’S, Newfoundland and Labrador, Dec. 10, 2025 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces the successful demonstration of its KATFISH Unmanned Surface Vessel Launch and Recovery System (USV-LARS) from TKMS ATLAS UK’s (ATLAS UK) 11-meter...

How Decades of Innovation Are Converging for Commercial Spider Silk Success DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB)(“the Company”, “Kraig”, “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering a defining phase in its corporate and scientific evolution. What began as a bold idea by Kim Thompson, Kraig’s founder and CEO, more than a decade ago, is now maturing into a viable business model blending genetic engineering, biotechnology, and commercial textile manufacturing. Kraig Labs’ journey, from acquiring key patent rights abandoned by a failed predecessor to developing proprietary gene-insertion...